Overview

* Cassava Sciences ( SAVA ) Q3 net loss narrows to $10.8 mln, beating analyst expectations

* Company advancing simufilam for TSC-related epilepsy, study planned for H1 2026

* Cash and cash equivalents at $106.1 mln, expected to support operations into 2027

Outlook

* Cassava plans proof-of-concept study for simufilam in TSC-related epilepsy in H1 2026

* Company revises cash use guidance downward for second half of 2025

* Cassava expects year-end 2025 cash balance between $92 mln and $96 mln

Result Drivers

* COST REDUCTION - Decrease in R&D and G&A expenses contributed to narrowed net loss for Q3 2025

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.22

Q3 Net Beat -$10.81 -$13 mln

Income mln (1

Analyst)

Q3 Beat -$11.86 -$14 mln

Operatin mln (1

g Income Analyst)

Q3 Basic -$0.22

EPS

Q3 $11.86

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Cassava Sciences Inc ( SAVA ) is $5.00, about 37.8% above its November 11 closing price of $3.11

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)